CA2474377A1 - Technique d'isolation du foie a effraction minimale aux fins de perfusion pour le traitement de metastases au foie - Google Patents
Technique d'isolation du foie a effraction minimale aux fins de perfusion pour le traitement de metastases au foie Download PDFInfo
- Publication number
- CA2474377A1 CA2474377A1 CA 2474377 CA2474377A CA2474377A1 CA 2474377 A1 CA2474377 A1 CA 2474377A1 CA 2474377 CA2474377 CA 2474377 CA 2474377 A CA2474377 A CA 2474377A CA 2474377 A1 CA2474377 A1 CA 2474377A1
- Authority
- CA
- Canada
- Prior art keywords
- liver
- pressure
- ihp
- intrahepatic
- occluding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 43
- 230000010412 perfusion Effects 0.000 title claims description 41
- 230000002440 hepatic effect Effects 0.000 title claims description 27
- 206010027457 Metastases to liver Diseases 0.000 title claims description 8
- 210000004185 liver Anatomy 0.000 claims abstract description 62
- 210000003240 portal vein Anatomy 0.000 claims description 35
- 210000003462 vein Anatomy 0.000 claims description 9
- 230000017531 blood circulation Effects 0.000 claims description 5
- 230000008337 systemic blood flow Effects 0.000 claims 3
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 abstract description 8
- 238000002955 isolation Methods 0.000 abstract description 6
- 230000002792 vascular Effects 0.000 abstract description 5
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 20
- 229960001924 melphalan Drugs 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 230000001839 systemic circulation Effects 0.000 description 11
- 241000282887 Suidae Species 0.000 description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
- 210000002989 hepatic vein Anatomy 0.000 description 7
- 102000003390 tumor necrosis factor Human genes 0.000 description 7
- 210000002767 hepatic artery Anatomy 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 3
- 206010019695 Hepatic neoplasm Diseases 0.000 description 3
- 235000013290 Sagittaria latifolia Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000015246 common arrowhead Nutrition 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 230000001085 cytostatic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- JJJFUHOGVZWXNQ-UHFFFAOYSA-N enbucrilate Chemical group CCCCOC(=O)C(=C)C#N JJJFUHOGVZWXNQ-UHFFFAOYSA-N 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000036828 Device occlusion Diseases 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000002048 axillary vein Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002697 interventional radiology Methods 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 201000002575 ocular melanoma Diseases 0.000 description 2
- 210000004258 portal system Anatomy 0.000 description 2
- 210000002563 splenic artery Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 1
- 108010002885 Polygeline Proteins 0.000 description 1
- 206010065647 Systemic leakage Diseases 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- MGCCHNLNRBULBU-WZTVWXICSA-N flunixin meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O MGCCHNLNRBULBU-WZTVWXICSA-N 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000002977 hyperthermial effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960000554 metrizamide Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- GVEAYVLWDAFXET-XGHATYIMSA-N pancuronium Chemical compound C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 GVEAYVLWDAFXET-XGHATYIMSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000013310 pig model Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 210000002796 renal vein Anatomy 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 210000000955 splenic vein Anatomy 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Surgical Instruments (AREA)
- Prostheses (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48816303P | 2003-07-18 | 2003-07-18 | |
| US60/488,163 | 2003-07-18 | ||
| US88890204A | 2004-07-09 | 2004-07-09 | |
| US10/888,902 | 2004-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2474377A1 true CA2474377A1 (fr) | 2005-01-18 |
Family
ID=34083428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2474377 Abandoned CA2474377A1 (fr) | 2003-07-18 | 2004-07-15 | Technique d'isolation du foie a effraction minimale aux fins de perfusion pour le traitement de metastases au foie |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP4786152B2 (fr) |
| CA (1) | CA2474377A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2805188C1 (ru) * | 2022-06-14 | 2023-10-11 | Государственное бюджетное учреждение Санкт-Петербургский научно-исследовательский институт скорой помощи им. И.И. Джанелидзе | Способ гибридной изолированной гипертермической химиоперфузии печени |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2330621C1 (ru) * | 2006-11-08 | 2008-08-10 | Николай Васильевич Рухляда | Способ снижения токсических эффектов химиопрепаратов во время изолированной перфузии печени |
| EP2633880A1 (fr) * | 2010-10-25 | 2013-09-04 | The Ritsumeikan Trust | Procédé de fonctionnement d'un dispositif d'administration d'une substance à introduire, et procédé d'administration d'une substance à introduire |
| JP2023523857A (ja) | 2020-05-04 | 2023-06-07 | ラトガーズ、ザ ステイト ユニバーシティ オブ ニュージャージー | 細胞の透過化およびトランスフェクションを強化するために吸引を使用するシステムおよび方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5723282A (en) * | 1991-07-08 | 1998-03-03 | The American National Red Cross | Method of preparing organs for vitrification |
| JPH1147265A (ja) * | 1997-07-29 | 1999-02-23 | Sumitomo Bakelite Co Ltd | ２バルーンカテーテル |
| KR100786028B1 (ko) * | 2000-02-03 | 2007-12-17 | 쿡 인코포레이티드 | 이식가능한 혈관장치 |
-
2004
- 2004-07-15 CA CA 2474377 patent/CA2474377A1/fr not_active Abandoned
- 2004-07-16 JP JP2004210272A patent/JP4786152B2/ja not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2805188C1 (ru) * | 2022-06-14 | 2023-10-11 | Государственное бюджетное учреждение Санкт-Петербургский научно-исследовательский институт скорой помощи им. И.И. Джанелидзе | Способ гибридной изолированной гипертермической химиоперфузии печени |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005040606A (ja) | 2005-02-17 |
| JP4786152B2 (ja) | 2011-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU762196B2 (en) | Circulatory support system and method of use for isolated segmental perfusion | |
| Kazui et al. | Selective cerebral perfusion during operation for aneurysms of the aortic arch: a reassessment | |
| CA2874661C (fr) | Catheters et procedes de commande pour une penetration pulmonaire et therapies associees | |
| Vahrmeijer et al. | Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver | |
| JP7679598B2 (ja) | 血管外空間の血管過灌流のための装置及び方法 | |
| US20240008932A1 (en) | Systems, devices and methods for resuscitation | |
| Aigner et al. | Drug filtration in high-dose regional chemotherapy | |
| WO2018230577A1 (fr) | Dispositif de perfusion et son procédé de fonctionnement | |
| Van Iersel et al. | Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: a clinical and pharmacologic evaluation | |
| Raaf | Administration of chemotherapeutic agents: techniques and controversies | |
| Quebbeman et al. | A technique for isolated hyperthermic liver perfusion | |
| Rothbarth et al. | An experimental minimally invasive perfusion technique for the treatment of liver metastases | |
| RU2065734C1 (ru) | Способ лечения опухолей паренхиматозных органов | |
| Weinreich et al. | Transarterial perfusion of liver metastases | |
| JP4786152B2 (ja) | 肝臓潅流分離法 | |
| RU2826473C2 (ru) | Способ эндоваскулярной артерио-порто-кавальной изолированной химиоперфузии печени | |
| Ku et al. | Percutaneous hepatic venous isolation and extracorporeal charcoal hemoperfusion for high-dose intraarterial chemotherapy in patients with colorectal hepatic metastases | |
| English | Direct left ventriculofemoral bypass during resection of coarctation of the aorta with anomalous subclavian arteries | |
| Polycarpou et al. | Cardiopulmonary Bypass and Cardioplegia | |
| JPH1147265A (ja) | ２バルーンカテーテル | |
| Ku et al. | Direct hemoperfusion under infrahepatic inferior vena caval isolation for the Intraarterial Chemotherapy of Pelvic Tumors | |
| Tolleth et al. | Regional isolation perfusion in the treatment of advanced malignant disease | |
| Sato et al. | Two cases of chronic pulmonary thromboembolism saved by postoperative use of a percutaneous cardiopulmonary support device | |
| Dunn et al. | The Femoral Catheter | |
| Charlesworth et al. | Vascular access |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |